Greenwich LifeSciences Provides Updates on Phase III FLAMINGO-01 Clinical Trial and Corporate Strategy
STAFFORD, Texas, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
